Mednet Logo
HomeHematology
Hematology

Hematology

Clinical discussions on blood disorders, coagulation, transfusion medicine, and hematologic malignancies.

Recent Discussions

How do you approach prophylactic antibiotics in patients who continue to have recurrent neutropenic fever following chemotherapy for solid tumors despite chemotherapy dose reduction and growth factor support?

2 Answers

Mednet Member
Mednet Member
Infectious Disease · Johns Hopkins University

This has to be individualized to the patient. It depends on the length of neutropenia, previous infections, and local antibiotic resistance. If the patient develops neutropenic fever after every cycle of chemotherapy and no obvious nidus of infection has been identified, a trial of a fluoroquinolone...

In older male patients with a history of underlying autoimmune disease, what clinical manifestations would prompt you to evaluate for VEXAS Syndrome? 

5
1 Answers

Mednet Member
Mednet Member
Rheumatology · University of Maryland School of Medicine

Hello!!!Skin lesions, elevated MCV, elevated inflammatory markers.

How should community oncologists practically counsel patients with aggressive lymphomas on the potential treatment course as they move into 2L/3L therapies?

1 Answers

Mednet Member
Mednet Member
Medical Oncology · Memorial Sloan Kettering

For those who relapse after first line therapy, treatment recommendations are dependent on the timing of relapse. For those who relapse within 12 months of completing first-line therapy and are fit, I would strongly consider referral to a center with CAR T-cell capabilities. As noted before, 5-year ...

Which patients with relapsed/refractory NHL are appropriate for pre-CAR-T bridging radiation therapy?

2
2 Answers

Mednet Member
Mednet Member
Radiation Oncology · Mayo Clinic

Before answering this important question, I think that we, as Radiation Oncologists, should give serious consideration to moving past the terminology of "bridging radiation therapy" and instead refer to it as "pre-CAR-T infusion radiation therapy." Bridging therapy was initially an apt name; we were...

In addition to monitoring hemoglobin and supplementing folic acid, what is your approach to hereditary spherocytosis in pregnancy?

1 Answers

Mednet Member
Mednet Member
Hematology · University of Pittsburgh

I use the same transfusion threshold for the general pregnant population but I do refer to maternofetal medicine/high risk pregnancy clinic for closer fetal monitoring. My personal preference is to obtain genetic testing to confirm the specific mutation responsible for hereditary spherocytosis as it...

What vitamins and minerals do you check yearly for patients post gastric bypass surgery?

1
1 Answers

Mednet Member
Mednet Member
Hospital Medicine · Emory University Hospital

Following Roux-en-Y gastric bypass it is essential to monitor micronutrients, vitamins, and minerals because malabsorption and long-term complications may occur with improper care. Based on ASMBS 2016 Nutrition Guidelines, AACE/TOS/ASMBS 2019 updates, and Endocrine Society recommendations, here are ...

How do you manage B12 deficiency refractory to subcutaneous replacement?

2 Answers

Mednet Member
Mednet Member
Hematology · Gundersen Health

I tend to start with IM injections of B12 when patients are severely deficient. The most common mistake in replacing severely low B12 is to not load, or to check levels too early. I have not used SQ administration before. It should absorb, but if you are having issues I would go to IM and start week...

Would you give GO and/or a FLT3 inhibitor for patients with AML with t(8;21) and FLT3-ITD low in addition to 7+3?

1 Answers

Mednet Member
Mednet Member
Hematology · University of Chicago

First, in terms of risk stratification, core binding factor (CBF) AML [whether inv16 or t(8;21)] is considered to be favorable risk by ELN22 even if a FLT3 mutation is present (Döhner et al., PMID 35797463). The incidence of FLT3-ITD in CBF-AML is 5-10% (Faber et al., PMID 27798625). There are some ...

For which rituximab infusion reaction symptoms do you consider it safe to re-challenge in the office with adjusted rates and pre-medications?

1 Answers

Mednet Member
Mednet Member
Rheumatology · The Feinberg School of Medicine, Northwestern University

When deciding whether it is safe to re-challenge with rituximab after an infusion reaction, the most important consideration is the type of reaction that the patient experienced. This will help to risk stratify and determine whether same day or future infusions of RTX should be used. Importantly, th...

Do you hold maintenance lenalidomide or bortezomib for a patient who needs a surgery?

4
1 Answers

Mednet Member
Mednet Member
Medical Oncology · University of Michigan

I'm not aware of any formal data to guide this recommendation. In general, I do not recommend holding maintenance lenalidomide or bortezomib for surgery. I do hold maintenance for treatment if/when: - the patient has cytopenias from treatment and would benefit from improved counts from a treatment b...